glp 1 drugs wikipedia Semaglutide GLP-1 | Summary

When Should I See a Doctor

[PMID 38958939, PMID 39976940, PMID 42060879] CONTRAINDICATIONS A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy PRECAUTIONS Kidney disease No dose adjustment is necessary for any degree of renal impairment Liver disease No dose adjustment is necessary for any degree of hepatic impairment Stomach disorders Wegovy slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like Wegovy, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures

Other serious side effects are kidney failure, pancreatitis, and gallbladder problems

10.1016/j.atherosclerosis.2012.05.007

Following the acquisition phase, liraglutide (25 g/kg, i.p., daily) was administered beginning on the final day of self-administration and continued through extinction and reinstatement testing

Cannon CP, Pratley R, Dagogo-Jack S, et al